Discover Opportunities months before the RFP drops
Learn more →Retrieving contract details... Hang tight!
See what competitors charge and their contract structure
Spot renewal opportunities 6-12 months before expiration
Analyze buyer's purchasing history and vendor preferences
Track expiration dates across all your target accounts
Reach decision-makers before renewal with competitive intel
Our customers win 3x more contract renewals and replacements
Premium
Clean & enrich your CRM automatically
Premium
Get complete source documentation & analysis
This contract includes 1 purchase order from Jun 28, 2024 to Jun 28, 2024
| Buyer | Vendor | Issued Date | Quantity |
|---|---|---|---|
| Office of Acquisition Managementt Policy | CURIEDX, INC | Jun 28, 2024 | 1 |
Full Purchase Intelligence Available
Get complete pricing, descriptions, and financial details for all 1 purchase orders
Unlock Full Details →See what competitors charge and their contract structure
Spot renewal opportunities 6-12 months before expiration
Analyze buyer's purchasing history and vendor preferences
Track expiration dates across all your target accounts
Reach decision-makers before renewal with competitive intel
Our customers win 3x more contract renewals and replacements
No public files available for this contract.
Contract documentation may be available through official government sources or agency portals. Starbridge can help you track down and retrieve these files.
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO DEVELOP AND COMMERCIALIZE A RAPID PHENOTYPIC ANTIMICROBIAL SUSCEPTIBILITY TESTING (AST) SYSTEM THAT WILL DELIVER RESULTS FOR DEFINITIVE THERAPEUTIC DECISIONS WITHIN 4 TO 6 HOURS FROM COLONIES ON A CULTURE
Effective Date
Sep 30, 2022
Expires
Effective: Sep 30, 2022
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO DEVELOP AND COMMERCIALIZE A RAPID PHENOTYPIC ANTIMICROBIAL SUSCEPTIBILITY TESTING (AST) SYSTEM THAT WILL DELIVER RESULTS FOR DEFINITIVE THERAPEUTIC DECISIONS WITHIN 4 TO 6 HOURS FROM COLONIES ON A CULTURE
ActiveTHIS CONTRACT INCLUDES PRECLINICAL AND MANUFACTURING DEVELOPMENT ACTIVITIES INCLUDING CELL LINE DEVELOPMENT PROCESS DEVELOPMENT NON-CLINICAL EFFICACY STUDIES NON-CLINICAL SAFETY STUDIES MANUFACTURING ACTIVITIES CLINICAL ACTIVITIES AND ALL AS
Effective Date
Sep 26, 2019
Expires
Effective: Sep 26, 2019
THIS CONTRACT INCLUDES PRECLINICAL AND MANUFACTURING DEVELOPMENT ACTIVITIES INCLUDING CELL LINE DEVELOPMENT PROCESS DEVELOPMENT NON-CLINICAL EFFICACY STUDIES NON-CLINICAL SAFETY STUDIES MANUFACTURING ACTIVITIES CLINICAL ACTIVITIES AND ALL AS
ActiveTHIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION.
Effective Date
Sep 28, 2022
Expires
Effective: Sep 28, 2022
THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION.
ActiveTHE OVERALL OBJECTIVE OF THIS SOW IS TO CREATE A PARTNERSHIP BETWEEN THE AGREEMENT RECIPIENT, DUKE UNIVERSITY ON BEHALF OF DUKE CLINICAL RESEARCH INSTITUTE (DCRI), AND BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY (BARDA) TO ENHANCE INNOVATI
Effective Date
Sep 29, 2024
Expires
Effective: Sep 29, 2024
THE OVERALL OBJECTIVE OF THIS SOW IS TO CREATE A PARTNERSHIP BETWEEN THE AGREEMENT RECIPIENT, DUKE UNIVERSITY ON BEHALF OF DUKE CLINICAL RESEARCH INSTITUTE (DCRI), AND BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY (BARDA) TO ENHANCE INNOVATI
ActiveSee who's winning contracts, track spending trends, and identify your best opportunities before your competition.
Schedule Your Demo →Premium
Clean & enrich your CRM automatically
Premium
Get complete source documentation & analysis